clofibric acid has been researched along with Parkinson Disease in 2 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mutez, E | 1 |
| Duhamel, A | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Destée, A | 1 |
| Kreisler, A | 1 |
| Becker, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
2 other studies available for clofibric acid and Parkinson Disease
| Article | Year |
|---|---|
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease.
Topics: Clofibric Acid; Diabetes Complications; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2009 |
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Topics: Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Clofibric Acid; Comorbidity; Databas | 2008 |